Tabula Rasa HealthCare has completed the acquisition of DoseMe.

DoseMe’s advanced precision dosing tool DoseMeRx™ and Tabula’s Medication Risk Mitigation (MRM) technologies will improve the safety measures related to medication dosing and enhance its availability in the hospital settings and healthcare system worldwide.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

DoseMeRx™, in combination with Tabula’s technologies, will help in improving the safety, quality, and cost efficiency of the patient care.

Tabula Rasa Healthcare is a healthcare technology company based in the US, while DoseMe is a medical technology company based in Australia.

Generex Biotechnology has completed 51% stake acquisition in Olaregen Therapeutix.

Olaregen received $400,000 as an upfront payment from Generex as part of the transaction, and is also eligible to receive $11.6m as milestone payments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Flex Pharmaceuticals has signed a definitive merger agreement with Salarius Pharmaceuticals.”

The acquisition added Olaregen’s FDA-cleared wound healing product Excellagen® to Generex’s portfolio. The product has received approval for the treatment of 17 different types of wounds.

Generex plans to accelerate the launch of Excellagen® for various indications in different markets.

Generex and Olaregen are biotechnology companies based in Canada and the US respectively.

Flex Pharmaceuticals has signed a definitive merger agreement with Salarius Pharmaceuticals.

Salarius will be merged with a subsidiary of Flex and the combined company will be named Salarius.

The merged entity will focus on accelerating Salarius’ pipeline of epigenetic therapies for rare and orphan cancers.

Stakeholders of Flex will hold 19.9% interest in the combined company and the right to receive warrants after six months of closing the transaction.

Salarius Pharmaceuticals is an oncology-focussed biotechnology company, while Flex Pharmaceuticals is a biotechnology company focused on neurology.

Both companies involved in the merger are based in the US.